The FDA said that giving the recalled drug to patients with a lidocaine allergy could cause a potentially life-threatening allergic reaction. No adverse events have been reported, the drugmaker said Nov. 19.
Fresenius Kabi is asking its customers to check their stock immediately and quarantine any of the affected product.
Read the full news release here.
More articles on pharmacy:
Eli Lilly’s arthritis drug gets emergency approval as COVID-19 treatment
Pfizer applies for COVID-19 vaccine emergency approval
WHO: Stop giving COVID-19 patients remdesivir
